These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10413072)

  • 41. Predictors of torsades de pointes in rabbit ventricles perfused with sedating and nonsedating histamine H1-receptor antagonists.
    Gilbert JD; Cahill SA; McCartney DG; Lukas A; Gross GJ
    Can J Physiol Pharmacol; 2000 May; 78(5):407-14. PubMed ID: 10841436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin.
    Honig PK; Woosley RL; Zamani K; Conner DP; Cantilena LR
    Clin Pharmacol Ther; 1992 Sep; 52(3):231-8. PubMed ID: 1526078
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
    Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
    J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of cisapride on QT interval in children.
    Khongphatthanayothin A; Lane J; Thomas D; Yen L; Chang D; Bubolz B
    J Pediatr; 1998 Jul; 133(1):51-6. PubMed ID: 9672510
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Additive Proarrhythmic Effect of Combined Treatment with QT-Prolonging Agents.
    Frommeyer G; Fischer C; Ellermann C; Dechering DG; Kochhäuser S; Lange PS; Wasmer K; Fehr M; Eckardt L
    Cardiovasc Toxicol; 2018 Feb; 18(1):84-90. PubMed ID: 28612303
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias.
    Giudicessi JR; Ackerman MJ; Camilleri M
    Neurogastroenterol Motil; 2018 Jun; 30(6):e13302. PubMed ID: 29441683
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Long QT interval and malignant ventricular arrhythmia during treatment with cisapride. Report of a clinical case].
    Massari FM; Trevano FQ; Diehl L; Romano S
    Ital Heart J Suppl; 2000 Aug; 1(8):1055-8. PubMed ID: 10993015
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchiectomized male rabbits.
    Liu XK; Katchman A; Whitfield BH; Wan G; Janowski EM; Woosley RL; Ebert SN
    Cardiovasc Res; 2003 Jan; 57(1):28-36. PubMed ID: 12504811
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Retrospective analysis of the effects of cisapride on the QT interval and QT dispersion in chronic hemodialysis patients.
    Mathis AS; Costeas C; Barone JA
    Am J Kidney Dis; 2001 Dec; 38(6):1284-91. PubMed ID: 11728962
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The proarrhythmogenic activity of non-anti-arrhythmia drugs. Is treatment with antihistamines and cisapride safe?].
    Pelov R; Tankova L; Krushkov I
    Vutr Boles; 1999; 31(2-3):5-9. PubMed ID: 10847134
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of cisapride on the corrected QT interval and QT dispersion in premature infants.
    Cools F; Benatar A; Bougatef A; Vandenplas Y
    J Pediatr Gastroenterol Nutr; 2001 Aug; 33(2):178-81. PubMed ID: 11568520
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
    Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
    Eur J Pharmacol; 2007 Dec; 577(1-3):222-32. PubMed ID: 18074444
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of 5-HT4-receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles.
    Kii Y; Ito T
    J Cardiovasc Pharmacol; 1997 May; 29(5):670-5. PubMed ID: 9213211
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of erythromycin and cisapride on emptying of the vagally denervated intrathoracic stomach.
    Narasimhan R; Mittal BR; Gupta NM
    Trop Gastroenterol; 2002; 23(3):122-4. PubMed ID: 12693153
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug interactions with cisapride: clinical implications.
    Michalets EL; Williams CR
    Clin Pharmacokinet; 2000 Jul; 39(1):49-75. PubMed ID: 10926350
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of gastrointestinal prokinetic agents, TKS159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring.
    Sugiyama A; Hashimoto K
    Toxicol Appl Pharmacol; 1998 Sep; 152(1):261-9. PubMed ID: 9772221
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparison of the pharmacokinetics of two dosing regimens of cisapride and their effects on corrected QT interval in premature infants.
    Cools F; Benatar A; Bruneel E; Theyskens C; Bougatef A; Casteels A; Vandenplas Y
    Eur J Clin Pharmacol; 2003 May; 59(1):17-22. PubMed ID: 12682804
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres.
    Puisieux FL; Adamantidis MM; Dumotier BM; Dupuis BA
    Br J Pharmacol; 1996 Apr; 117(7):1377-9. PubMed ID: 8730728
    [TBL] [Abstract][Full Text] [Related]  

  • 59. "Conventional" antihistamines slow cardiac repolarization in isolated perfused (Langendorff) feline hearts.
    Wang WX; Ebert SN; Liu XK; Chen YW; Drici MD; Woosley RL
    J Cardiovasc Pharmacol; 1998 Jul; 32(1):123-8. PubMed ID: 9676731
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of tegaserod in critically ill patients with impaired gastric motility.
    Banh HL; MacLean C; Topp T; Hall R
    Clin Pharmacol Ther; 2005 Jun; 77(6):583-6. PubMed ID: 15961989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.